CLLS
Cellectis S.A. American Depositary Shares
Biological Products, (No Diagnostic Substances)
Best Biotech Stocks 2026 →
Cellectis (CLLS) Stock: Buy, Sell, or Hold?
$1.33
-0.05 (-3.62%)
▼
5d:
+29.13%
30d:
+18.75%
90d:
-56.39%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (21%)
Quality Score
32/100
Position
EXTENDED
30-Day Fair Range
$0.99 – $1.27
Position: EXTENDED
Forward P/E & Valuation
-1.9x
Next 12M consensus est.
Wall Street Target
$4.83
+262.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$1.00 / $1.53
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: CLLS shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $1.33, which is considered extended relative to its 30-day fair value range of $0.99 to $1.27.
Technical Outlook: Technically, CLLS is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.53. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: CLLS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.83 (+262.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLLS is in a strong downtrend. Immediate support is located at $1.00, while resistance sits at $1.53. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: CLLS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.83 (+262.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.99 -
$1.27
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
Trading Range & Key Levels
30-Day Trading Range
$0.99 -
$1.27
Current vs Trading Range
EXTENDED
Support Level
$1.00
Resistance Level
$1.53
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 262.8% below Wall St target ($4.83)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.86
Wall Street Target
$4.83
(+262.8%)
Revenue Growth (YoY)
-62.1%
Profit Margin
-102.3%
Share CLLS Analysis
Share this live CLLS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 12, 2026 9:03 PM ET
Data refreshes hourly during market hours. Next update: 10:03 PM
Data refreshes hourly during market hours. Next update: 10:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 37 SELL |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$64 | 48 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CLLS Research Pages
